CAJ | 학술논문

目的探讨COBDP方案和改良后的INBDP联合化疗方案在治疗非霍奇金淋巴瘤中的临床近期疗效和毒副反应。方法以异环磷酰胺，诺维本分别替代COBDP联合化疗方案中的环磷酰胺和长春新碱。两种方案共治疗非霍奇金淋巴瘤73例进行疗效比较，以χ2和P值检验。结果 INBDP方案组CR率79.3 %，优于COBDP方案组的56.9 %，(χ2=3.926，P＜0.05)。INBDP方案组RR率93.1 %高于COBDP方案组81.8%，(χ2=1.883，P＜0.05)。两组方案的副反应均表现在骨髓抑制方面，INBDP方案组比COBDP明显。
목적탐토COBDP방안화개량후적INBDP연합화료방안재치료비곽기금림파류중적림상근기료효화독부반응。방법이이배린선알，낙유본분별체대COBDP연합화료방안중적배린선알화장춘신감。량충방안공치료비곽기금림파류73례진행료효비교，이χ2화P치검험。결과 INBDP방안조CR솔79.3 %，우우COBDP방안조적56.9 %，(χ2=3.926，P＜0.05)。INBDP방안조RR솔93.1 %고우COBDP방안조81.8%，(χ2=1.883，P＜0.05)。량조방안적부반응균표현재골수억제방면，INBDP방안조비COBDP명현。
Objective　To study the clinical response and toxic action of patients with non-Hodgkin's lymphoma treated with COBDP or improved INBDP chemotherapy. Methods　The improved INBDP regimen used Ifosfamide (IFO) and Vinorelbine (NVB) to substitute cyclophosphomide (CTX) and Vincristine (VCR), 29 and 44 cases respectively. Results　The CR rates of these 2 groups were 79.3 % and 56.8 % respectively. The main toxic action was myelosuppression in both groups, but the improved INBDP group is better than the COBDP group. Conclusion　The improved INBDP regimen is a more effective and less toxic regimen than the ordinary COBDP regimen in the treatment of non-Hodgikin's lymphoma.